Search





Search





Markets
/
Stocks
/
nasdaq-cor
/

Cencora Inc

COR

Add to Watchlist

261.080USD

+5.420+2.12%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

50.79BMarket Cap

19.91P/E TTM



Cencora Inc

261.080

+5.420+2.12%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cencora Inc

Currency: USD Updated: 2026-05-08

Key Insights

Cencora Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 394.95.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cencora Inc's Score

Industry at a Glance

Industry Ranking

39 / 206

Overall Ranking

119 / 4494

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cencora Inc Highlights

StrengthsRisks

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 321.33B.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.56% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 28.12%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 28.12%.

Undervalued

The company’s latest PE is 19.91, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 187.12M shares, decreasing 0.08% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 5.82K shares of this stock.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

394.950

Target Price

+30.06%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Cencora Inc is 5.68, ranking 191 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 78.36B, representing a year-over-year increase of 3.85%, while its net profit experienced a year-over-year increase of 128.64%.

Score

Industry at a Glance

Previous score

5.68

Change



Financials

3.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

3.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.94

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.88

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.49

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cencora Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Cencora Inc is 8.18, ranking 44 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 19.91, which is 134.78% below the recent high of 46.73 and 10.70% above the recent low of 17.78.

Score

Industry at a Glance

Previous score

8.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/206

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Cencora Inc is 8.14, ranking 63 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 397.50, with a high of 417.00 and a low of 279.21.

Score

Industry at a Glance

Previous score

8.14

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

394.950

Target Price

+30.06%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

116

Total

Median

Average

Company name

Ratings

Analysts

Cencora Inc

COR

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Cencora Inc is 7.02, ranking 93 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 311.11 and the support level at 227.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.93

Change

0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-10.590

Sell

RSI(14)

24.230

Sell

STOCH(KDJ)(9,3,3)

21.771

Neutral

ATR(14)

11.516

High Vlolatility

CCI(14)

-142.287

Sell

Williams %R

78.932

Sell

TRIX(12,20)

-0.516

Sell

StochRSI(14)

35.896

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

275.808

Sell

MA10

292.463

Sell

MA20

304.722

Sell

MA50

324.159

Sell

MA100

337.400

Sell

MA200

327.806

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Cencora Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 96.79%, representing a quarter-over-quarter increase of 1.99%. The largest institutional shareholder is The Vanguard, holding a total of 22.81M shares, representing 11.72% of shares outstanding, with 6.78% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

23.53M

+0.94%

BlackRock Institutional Trust Company, N.A.

12.84M

+0.21%

State Street Investment Management (US)

9.31M

+1.25%

Walgreens Holding Co

7.47M

-28.01%

T. Rowe Price Investment Management, Inc.

6.70M

+160.07%

T. Rowe Price Associates, Inc.

Star Investors

6.63M

-9.87%

Geode Capital Management, L.L.C.

5.46M

+3.20%

Fidelity Management & Research Company LLC

5.12M

+73.88%

Wellington Management Company, LLP

4.54M

+14.22%

JP Morgan Asset Management

4.44M

+18.80%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cencora Inc is 9.61, ranking 3 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Cencora Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.